Steroids
Steroids and performance enhancers
Bronchogen 20 mg
Dragon Pharma Bronchogen 20 mg – Synthetic Tetrapeptide for Respiratory Research ✔ Synthetic AEDL tetrapeptide bioregulator ✔ Khavinson peptide class compound ✔ Studied for lung tissue regeneration ✔ USA domestic shipping available Dragon Pharma Bronchogen 20 mg is a synthetic tetrapeptide bioregulator with the amino acid sequence Ala-Glu-Asp-Leu (AEDL). As part of the well-characterized Khavinson peptide group, this compound has been the subject of experimental research focusing on lung tissue regeneration, DNA stabilization, and anti-inflammatory effects in respiratory models. Each vial contains 20 mg of lyophilized Bronchogen in a 2 mL format, requiring reconstitution with bacteriostatic water before use. Bronchogen represents a targeted approach to studying pulmonary tissue repair mechanisms and the molecular pathways underlying respiratory health. For related research compounds, explore our peptides category and specifically SS-31 50 mg for mitochondrial function studies. What Makes Bronchogen Valuable in Research? Bronchogen belongs to a class of short-chain peptides known for their bioregulatory properties. The AEDL sequence has been investigated for its ability to influence gene expression patterns associated with tissue-specific repair mechanisms. In preclinical respiratory models, Bronchogen has demonstrated potential for supporting cellular regeneration and modulating inflammatory responses. Researchers value Bronchogen for its targeted approach to pulmonary research. Its short sequence and defined mechanism of action make it a practical tool for investigating the molecular basis of lung tissue homeostasis and repair. For investigators exploring broader peptide-based interventions, Thymosin Alpha-1 offers complementary research avenues in immune modulation. Current scientific literature on Khavinson peptides, including Bronchogen, can be accessed through the PubMed database, where researchers can review peer-reviewed studies on their biological activity and experimental applications. Key Research Applications for Dragon Pharma Bronchogen ✔ Investigation of lung tissue regeneration mechanisms ✔ Evaluation of DNA stabilization in pulmonary cells ✔ Research on anti-inflammatory pathways in respiratory models ✔ Studies of peptide bioregulation in tissue repair ✔ Preclinical models of respiratory health and recovery For Research Purposes Only Bronchogen 20 mg is intended for research use only and is not approved for human consumption. Proper handling, reconstitution, and experimental protocols are essential for reliable results. For studies on regenerative peptides, BPC 157 represents another avenue for investigating tissue healing mechanisms.
Cardiogen 20 mg
Dragon Pharma Cardiogen 20 mg – Synthetic Tetrapeptide for Cardiovascular Research ✔ Synthetic AEDR tetrapeptide bioregulator ✔ Studied for cardioprotective mechanisms ✔ Regulates fibroblast activity & apoptosis ✔ USA domestic shipping available Dragon Pharma Cardiogen 20 mg is a synthetic tetrapeptide bioregulator with the amino acid sequence Ala-Glu-Asp-Arg (AEDR). This compound has been investigated in experimental models for its potential cardiovascular support properties, including regulation of fibroblast activity, protection of cardiac myocytes from programmed cell death, and promotion of tissue repair mechanisms. Each vial contains 20 mg of lyophilized Cardiogen in a 2 mL format, requiring reconstitution with bacteriostatic water before use. Cardiogen represents a targeted research tool for investigating the molecular pathways involved in cardiac tissue preservation and recovery. For related research compounds, explore our peptides category and specifically SS-31 50 mg for mitochondrial function studies. What Makes Cardiogen Valuable in Research? Cardiogen belongs to a class of short-chain peptides known for their tissue-specific bioregulatory properties. The AEDR sequence has been studied for its ability to influence cellular processes relevant to cardiovascular health, including the modulation of fibroblast activity, inhibition of apoptosis in cardiac muscle cells, and support of regenerative responses in cardiac tissue. Researchers value Cardiogen for its targeted approach to studying cardiac physiology. Its defined sequence and mechanism of action make it a practical tool for investigating the molecular basis of myocardial protection and repair. For investigators exploring broader cardiovascular research applications, MOTS-C offers complementary avenues in metabolic and cardiac function studies. Current scientific literature on Khavinson peptides, including Cardiogen, can be accessed through the PubMed database, where researchers can review peer-reviewed studies on their biological activity and experimental applications. Key Research Applications for Dragon Pharma Cardiogen ✔ Investigation of cardiac fibroblast regulation ✔ Evaluation of anti-apoptotic mechanisms in cardiomyocytes ✔ Research on myocardial tissue repair and regeneration ✔ Studies of peptide bioregulation in cardiovascular models ✔ Preclinical models of cardiac protection and recovery For Research Purposes Only Cardiogen 20 mg is intended for research use only and is not approved for human consumption. Proper handling, reconstitution, and experimental protocols are essential for reliable results. For studies on vascular health, TB 500 provides additional research avenues in tissue repair and angiogenesis.
Cartalax 20 mg
Dragon Pharma Cartalax 20 mg – Synthetic Tripeptide for Cartilage and Joint Research ✔ Synthetic AED tripeptide bioregulator ✔ Peptide bioregulator for connective tissue ✔ Studied for cartilage and joint support ✔ USA domestic shipping available Dragon Pharma Cartalax 20 mg is a synthetic short tripeptide with the amino acid sequence Ala-Glu-Asp (AED). Classified as a peptide bioregulator, this compound has been studied preclinically for its potential to support cartilage, joint health, and connective tissue maintenance by influencing gene expression in chondrocytes and other joint-related cells. Each vial contains 20 mg of lyophilized Cartalax in a 2 mL format, requiring reconstitution with bacteriostatic water before use. Cartalax represents a targeted research tool for investigating the molecular mechanisms underlying cartilage maintenance, chondrocyte function, and the biological processes involved in joint health. For related research compounds, explore our peptides category and specifically BPC 157 for complementary tissue repair research applications. What Makes Cartalax Valuable in Research? Cartalax belongs to a class of short-chain peptides known for their tissue-specific bioregulatory properties. The AED sequence has been studied for its ability to influence cellular processes relevant to cartilage and joint biology, including the regulation of gene expression in chondrocytes and the modulation of connective tissue metabolism. Its defined sequence and mechanism of action make it a practical tool for investigating the molecular basis of cartilage maintenance and joint function. Researchers value Cartalax for its targeted approach to studying cartilage and connective tissue biology. Its ability to influence chondrocyte gene expression provides insights into the mechanisms that govern cartilage health and age-related changes in joint tissues. For investigators exploring other aspects of connective tissue research, TB 500 offers complementary research avenues in tissue repair and regeneration. Current scientific literature on peptide bioregulators can be accessed through the PubMed database, where researchers can review peer-reviewed studies on related compounds and experimental applications. Key Research Applications for Dragon Pharma Cartalax ✔ Investigation of chondrocyte gene expression and function ✔ Evaluation of cartilage maintenance and metabolism ✔ Research on connective tissue regulation and repair ✔ Studies of joint health and age-related changes ✔ Preclinical models of cartilage biology and joint function For Research Purposes Only Cartalax 20 mg is intended for research use only and is not approved for human consumption. Proper handling, reconstitution, and experimental protocols are essential for reliable results. For studies on wound healing and tissue repair, GHK-CU 50 mg provides additional research avenues in connective tissue regeneration.
